Influenza B virus in seals

Science

Volumn 288, Issue 5468, 2000, Pages 1051-1053

  Osterhaus, A D M E ^a,b   Rimmelzwaan, G F ^a   Martina, B E E ^a   Bestebroer, T M ^a   Fouchier, R A M ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Seal Rehabilitation and Research Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADOLESCENT; ANIMAL CELL; ANIMAL DISEASE; ANTIBODY RESPONSE; ARTICLE; INFLUENZA VIRUS B; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEAL; SEQUENCE ANALYSIS; SEROLOGY; SEROPREVALENCE; VIRUS INFECTION; VIRUS ISOLATION;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELLS, CULTURED; DISEASE RESERVOIRS; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, VIRAL; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA B VIRUS; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; PHARYNX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEALS, EARLESS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS SHEDDING;

EID: 0034640380     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.288.5468.1051     Document Type: Article

References (30)

1. B. R. Murphy and R. G. Webster, in Virology, B. N. Fields et al., Eds. (Raven, New York, 1990).
2. R. G. Webster, W. J. Bean, O. T. Gorman, T. M. Chambers, Y. Kawaoka, Microbiol. Rev. 56, 152 (1992).
3. C. P. Chang, A. E. New, J. F. Taylor, H. S. Chiang, Int. J. Zoon. 3, 61 (1976).
4. G. Takatsy, J. Romvary, E. Farkas, Acta Microbiol. Acad. Sci. Hung. 14, 309 (1967).
5. C. M. Prato, T. G. Akers, A. W. Smith, Nature 249, 255 (1974).
6. A. W. Smith and D. E. Skilling, J. Am. Vet. Med. Assoc. 175, 918 (1979).
7. A. D. Osterhaus et al., Arch. Virol. 86, 239 (1985).
8. A. D. Osterhaus and E. J. Vedder, Nature 335, 20 (1988).
9. A. D. Osterhaus et al., Nature 337, 21 (1989).
10. A. D. Osterhaus et al., Nature 388, 838 (1997).
11. C. D. Harvell et al., Science 285, 1505 (1999).
12. J. R. Geraci et al., Science 215, 1129 (1982).
13. V. S. Hinshaw et al., J. Virol. 51, 863 (1984).
14. R. G. Webster et al., Virology 113, 712 (1981).
15. R. J. Callan, G. Early, H. Kida, V. S. Hinshaw, J. Gen. Virol. 76, 199 (1995).
16. G. F. Rimmelzwaan, M. Baars, E. C. Claas, A. D. Osterhaus, J. Virol. Methods 74, 57 (1998).
17. A. D. Osterhaus, G. F. Rimmelzwaan, B. E. Martina, T. M. Bestebroer, R. A. Fouchier, unpublished data.
18. 2, 1 mM dNTP, and 400 nM each of primer. Cycling parameters were 30 min at 42°C, 4 min at 95°C, 1 min at 45°C, and 3 min at 72°C once; and then 1 min at 95°C, 1 min at 45°C, and 3 min at 72°C, repeated 39 times. PCR fragments were sequenced with a DYEnamic ET terminator cycle sequencing premix kit (Amersham) on an ABI-373A apparatus (Perkin Elmer).
19. 50 of influenza virus B/Seal/Netherlands/1/99 in DMEM supplemented with 4% bovine serum albumin, 1% L-glutamine, penicillin, and streptomycin. Influenza B virus infection was detected by immunofluorescence with influenza B NP-specific antibodies, which were labeled with fluorescein isothiocyanate (IMAGEN Influenza A+B, DAKO Diagnostics) after 24 hours. Cytopathic changes and HA activity (titer = 32) were detected in the culture cell after 48 hours.
20. J. T. Voeten et al., J. Clin. Microbiol. 36, 3527 (1998).
21. Antibody titers were determined with a recombinant fusion protein between maltose-binding protein (MBP) and NP or with HA/NA proteins purified from virions (both proteins were derived from B/Harbin/7/ 94). IgG antibody levels to HA/NA and NP proteins were determined by an indirect ELISA with antigen-coated plates and peroxidase-labeled protein A for detection. IgM antibody levels to NP were determined by means of an antibody-capture ELISA with goat anti-dog IgM-coated plates and peroxidase-labeled MBP-NP antigen for detection The goat antidog IgM antibody preparation specifically captures seal IgM, as was shown in routine serological tests for PDV and PHV.
22. I. M. Roitt, Essential Immunology (Blackwell Scientific, Oxford, ed. 8, 1994).
23. The sequences of influenza B virus HA and NS genes are available at www.flu.lanl.gov/.
24. Analysis of the HA1 sequences from human influenza B virus strains that are available from the influenza sequence database showed that between 1991 and 1999, the proportion of strains with >98% nucleotide identity to B/Seal/Netherlands/1/99 was 0, 17, 27, 46, 62, 29, 0, 0, and 0% of all epidemic strains for each successive year, respectively.
25. R. E. Shope, J. Exp. Med. 77, 111 (1943).
26. C. D. Wallace, J. Infect. Dis. 135, 490 (1977).
27. A. L. Frank et al., J. Infect. Dis. 144, 443 (1981).
28. C. B. Hall, R. G. Douglas, J. M. Geiman, M. P. Meagher, J. Infect. Dis. 140, 610 (1979).
29. HA1 sequences were amplified with M13-tagged primers P1 (5′-29M13-GCA TTT TCT AAT ATC CAC AA-3′) and P4 (5′-21M13-TTT GGG AAG CCA CCA ATC TG-3′) or primers P3 (5′-29M13-CCT ATA ATG CAC GAC AGA AC-3′) and P6 (5′-21M13-AAA CCA GCA ATA GCT CCG AA-3′), followed by sequencing with primers 29M13 (5′-CAG GAA ACA GCT ATG ACC-3′) and 21M13 (5′-TGT AAA ACG ACG GCC AGT-3′) using a DYEnamic ET terminator cycle sequencing premix kit (Amersham) and an ABI-373A sequencing apparatus (Perkin Elmer).
30. We are grateful to L. van der Kemp, C. de Mutsert, and M. van der Bildt for technical assistance; J. Habova for electron microscopy; Solvay Pharmaceuticals, Weesp, the Netherlands, for providing HA/NA proteins from B/Harbin/7/94; and the SRRC staff for taking care of and samples from seals. R. F. is a fellow of the Royal Netherlands Academy of Arts and Sciences.